Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis |
| September 15, 2018 | September 2018 Bond Updates |
|
TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ -- Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented... |
| View more at: https://www.prnewswire.com:443/news-releases/positive-phase-3-results-presented-for-dupixent-dupilumab-show-significant-improvement-on-multiple-measures-of-disease-severity-in-adolescents-with-moderate-to-severe-atopic-dermatitis-300713187.html |
| Related News |
|